Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) Target Price at $106.50

Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $106.50.

IRON has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. HC Wainwright raised their price target on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a report on Monday, August 17th.

Insider Buying and Selling at Disc Medicine

In other news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the sale, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $3,758,677.56. This represents a 25.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John D. Quisel sold 34,000 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $15,871,953.44. This represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 153,612 shares of company stock worth $11,431,811 over the last ninety days. Insiders own 3.76% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Disc Medicine by 22.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after acquiring an additional 2,807 shares during the period. Millennium Management LLC increased its stake in Disc Medicine by 1,277.1% in the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after purchasing an additional 100,620 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after purchasing an additional 3,454 shares during the last quarter. Legal & General Group Plc lifted its position in Disc Medicine by 18.0% in the second quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock valued at $1,276,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Disc Medicine by 21.6% during the second quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock valued at $891,000 after purchasing an additional 2,983 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $80.03 on Thursday. The stock has a market cap of $3.07 billion, a P/E ratio of -12.16 and a beta of 1.00. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $76.98 and its two-hundred day moving average price is $70.04. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.71) by $0.17. As a group, equities analysts predict that Disc Medicine will post -6.61 EPS for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.